Each of these steps can add months or even years to the timeline
Your individual results might differ from the above testimonials
When considering adding a GLP-1 receptor agonist like Rybelsus, NICE guidance indicates these agents may be appropriate for people with type 2 diabetes who: Have a BMI of 35 kg/m or higher (adjusted for ethnicity) and specific psychological or medical problems associated with obesity, or Have a BMI lower than 35 kg/m and for whom insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities GLP-1 therapy should only be continued if there is a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0%) and weight loss of at least 3% of initial body weight at six months
Banishing oily skin If you have oily skin, activated charcoal might just be the thing you need to help manage it
Supplementary information Rights and permissions About this article Cite this article Chen, Y., Xu, Yn., Ye, Cy
